Adicet Bio Company Insiders
| ACET Stock | USD 1.11 0.15 15.63% |
Adicet Bio employs about 143 people. The company is managed by 7 executives with a total tenure of roughly 334 years, averaging almost 47.0 years of service per executive, having 20.43 employees per reported executive. Breaking down Adicet Bio's management performance can provide insight into the firm performance.
Adicet Bio's Insider Buying Vs Selling
50
Selling | Buying |
Latest Trades
| 2024-06-05 | Michael Kauffman | Disposed 5900 @ 1.43 | View | ||
| 2024-01-25 | Orbimed Advisors Llc | Acquired 3125000 @ 2.4 | View |
Monitoring Adicet Bio's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Adicet |
Adicet Bio Management Team Effectiveness
The company has return on total asset (ROA) of (0.293) % which means that it has lost $0.293 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5791) %, meaning that it created substantial loss on money invested by shareholders. Adicet Bio's management efficiency ratios could be used to measure how well Adicet Bio manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to -0.65 in 2024. Return On Capital Employed is likely to gain to -0.77 in 2024. Total Current Liabilities is likely to drop to about 18.3 M in 2024. Liabilities And Stockholders Equity is likely to drop to about 165.2 M in 2024Common Stock Shares Outstanding is likely to drop to about 28 M in 2024
Adicet Bio Workforce Comparison
Adicet Bio is rated below average in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 768,668. Adicet Bio adds roughly 143 in number of employees claiming only tiny portion of equities under Health Care industry.
Adicet Bio Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Adicet Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Adicet Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Adicet Bio insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Schor Chen over a month ago Acquisition by Schor Chen of 421600 shares of Adicet Bio at 2.14 subject to Rule 16b-3 | ||
Aya Jakobovits over three months ago Disposition of 26400 shares by Aya Jakobovits of Adicet Bio at 2.14 subject to Rule 16b-3 | ||
Aya Jakobovits over three months ago Acquisition by Aya Jakobovits of 5900 shares of Adicet Bio subject to Rule 16b-3 | ||
Sanna Bastiano over six months ago Disposition of 28828 shares by Sanna Bastiano of Adicet Bio at 12.0 subject to Rule 16b-3 | ||
Schor Chen over a year ago Acquisition by Schor Chen of 240000 shares of Adicet Bio subject to Rule 16b-3 | ||
Schor Chen over a year ago Sale by Schor Chen of 5500 shares of Adicet Bio | ||
Silverstein Jonathan over a year ago Conversion by Silverstein Jonathan of 2425482 shares of Adicet Bio | ||
Schor Chen over a year ago Bona fide gift to Schor Chen of 26712 shares of Adicet Bio subject to Section 16 |
Adicet Bio Notable Stakeholders
An Adicet Bio stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Adicet Bio often face trade-offs trying to please all of them. Adicet Bio's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Adicet Bio's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Francesco MD | Chief VP | Profile | |
| BA CPA | Pres CEO | Profile | |
| Blake Aftab | Senior Officer | Profile | |
| Donald Healey | Chief Officer | Profile | |
| Amy Locke | Head Resources | Profile | |
| Brian Harvey | Chief Officer | Profile | |
| Aya Jakobovits | Founder Director | Profile |
About Adicet Bio Management Performance
The success or failure of an entity such as Adicet Bio often depends on how effective the management is. Adicet Bio management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Adicet management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Adicet management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.69) | (0.65) | |
| Return On Capital Employed | (0.81) | (0.77) | |
| Return On Assets | (0.69) | (0.65) | |
| Return On Equity | (0.84) | (0.80) |
Please note, the imprecision that can be found in Adicet Bio's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Adicet Bio. Check Adicet Bio's Beneish M Score to see the likelihood of Adicet Bio's management manipulating its earnings.
Adicet Bio Workforce Analysis
Traditionally, organizations such as Adicet Bio use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Adicet Bio within its industry.Adicet Bio Manpower Efficiency
Return on Adicet Bio Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 997.6K | |
| Net Loss Per Executive | 20.4M | |
| Working Capital Per Employee | 999.9K | |
| Working Capital Per Executive | 20.4M |
Additional Tools for Adicet Stock Analysis
When running Adicet Bio's price analysis, check to measure Adicet Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adicet Bio is operating at the current time. Most of Adicet Bio's value examination focuses on studying past and present price action to predict the probability of Adicet Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adicet Bio's price. Additionally, you may evaluate how the addition of Adicet Bio to your portfolios can decrease your overall portfolio volatility.